Impact of Tumor Genomic Mutations on Thrombotic Risk in Cancer Patients
Venous thromboembolism (VTE) is common in patients with cancer and is an important contributor to morbidity and mortality in these patients. Early thromboprophylaxis initiated only in those cancer patients at highest risk for VTE would be optimal. Risk stratification scores incorporating tumor locat...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2020-07-01
|
| Series: | Cancers |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2072-6694/12/7/1958 |
| _version_ | 1797561997646102528 |
|---|---|
| author | Orly Leiva Jean M. Connors Hanny Al-Samkari |
| author_facet | Orly Leiva Jean M. Connors Hanny Al-Samkari |
| author_sort | Orly Leiva |
| collection | DOAJ |
| description | Venous thromboembolism (VTE) is common in patients with cancer and is an important contributor to morbidity and mortality in these patients. Early thromboprophylaxis initiated only in those cancer patients at highest risk for VTE would be optimal. Risk stratification scores incorporating tumor location, laboratory values and patient characteristics have attempted to identify those patients most likely to benefit from thromboprophylaxis but even well-validated scores are not able to reliably distinguish the highest-risk patients. Recognizing that tumor genetics affect the biology and behavior of malignancies, recent studies have explored the impact of specific molecular aberrations on the rate of VTE in cancer patients. The presence of certain molecular aberrations in a variety of different cancers, including lung, colon, brain and hematologic tumors, have been associated with an increased risk of VTE and arterial thrombotic events. This review examines the findings of these studies and discusses the implications of these findings on decisions relating to thromboprophylaxis use in the clinical setting. Ultimately, the integration of tumor molecular genomic information into clinical VTE risk stratification scores in cancer patients may prove to be a major advancement in the prevention of cancer-associated thrombosis. |
| first_indexed | 2024-03-10T18:22:24Z |
| format | Article |
| id | doaj.art-0ba48e74b9124e78a52f217e77422ecb |
| institution | Directory Open Access Journal |
| issn | 2072-6694 |
| language | English |
| last_indexed | 2024-03-10T18:22:24Z |
| publishDate | 2020-07-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Cancers |
| spelling | doaj.art-0ba48e74b9124e78a52f217e77422ecb2023-11-20T07:14:27ZengMDPI AGCancers2072-66942020-07-01127195810.3390/cancers12071958Impact of Tumor Genomic Mutations on Thrombotic Risk in Cancer PatientsOrly Leiva0Jean M. Connors1Hanny Al-Samkari2Department of Medicine, Brigham and Women’s Hospital, Boston, MA 02215, USAHarvard Medical School, Boston, MA 02215, USAHarvard Medical School, Boston, MA 02215, USAVenous thromboembolism (VTE) is common in patients with cancer and is an important contributor to morbidity and mortality in these patients. Early thromboprophylaxis initiated only in those cancer patients at highest risk for VTE would be optimal. Risk stratification scores incorporating tumor location, laboratory values and patient characteristics have attempted to identify those patients most likely to benefit from thromboprophylaxis but even well-validated scores are not able to reliably distinguish the highest-risk patients. Recognizing that tumor genetics affect the biology and behavior of malignancies, recent studies have explored the impact of specific molecular aberrations on the rate of VTE in cancer patients. The presence of certain molecular aberrations in a variety of different cancers, including lung, colon, brain and hematologic tumors, have been associated with an increased risk of VTE and arterial thrombotic events. This review examines the findings of these studies and discusses the implications of these findings on decisions relating to thromboprophylaxis use in the clinical setting. Ultimately, the integration of tumor molecular genomic information into clinical VTE risk stratification scores in cancer patients may prove to be a major advancement in the prevention of cancer-associated thrombosis.https://www.mdpi.com/2072-6694/12/7/1958molecular subtypecancervenous thromboembolismarterial thrombosisALKROS1 |
| spellingShingle | Orly Leiva Jean M. Connors Hanny Al-Samkari Impact of Tumor Genomic Mutations on Thrombotic Risk in Cancer Patients Cancers molecular subtype cancer venous thromboembolism arterial thrombosis ALK ROS1 |
| title | Impact of Tumor Genomic Mutations on Thrombotic Risk in Cancer Patients |
| title_full | Impact of Tumor Genomic Mutations on Thrombotic Risk in Cancer Patients |
| title_fullStr | Impact of Tumor Genomic Mutations on Thrombotic Risk in Cancer Patients |
| title_full_unstemmed | Impact of Tumor Genomic Mutations on Thrombotic Risk in Cancer Patients |
| title_short | Impact of Tumor Genomic Mutations on Thrombotic Risk in Cancer Patients |
| title_sort | impact of tumor genomic mutations on thrombotic risk in cancer patients |
| topic | molecular subtype cancer venous thromboembolism arterial thrombosis ALK ROS1 |
| url | https://www.mdpi.com/2072-6694/12/7/1958 |
| work_keys_str_mv | AT orlyleiva impactoftumorgenomicmutationsonthromboticriskincancerpatients AT jeanmconnors impactoftumorgenomicmutationsonthromboticriskincancerpatients AT hannyalsamkari impactoftumorgenomicmutationsonthromboticriskincancerpatients |